Nevirapine Extended-Release Formulation Tablets in HIV-1-Infected Children-Long-term Follow-up

被引：2

作者：

Anabwani, Gabriel ^{[1
]}

Koenigs, Christoph ^{[2
]}

Giaquinto, Carlos ^{[3
]}

Aslanyan, Stella ^{[4
]}

Sabo, John P. ^{[4
]}

Morrow, J. -Scott ^{[4
]}

Feiterna-Sperling, Cornelia ^{[5
]}

机构：

[1] Botswana Baylor Childrens Clin Ctr Excellence, Gaborone, Botswana

[2] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Pediat, Frankfurt, Germany

[3] Univ Padua, Dept Womens & Childrens Hlth, I-35100 Padua, Italy

[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

[5] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany

来源：

CLINICAL INFECTIOUS DISEASES | 2015年 / 61卷 / 03期

关键词：

HIV-1; pediatric patients; long-term follow-up; extended-release formulation; nevirapine; SAFETY; EFFICACY;

D O I：

10.1093/cid/civ340

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received >= 48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.

引用

页码：476 / 479

页数：4

共 9 条

[1]

[Anonymous], TREATM CHILDR LIV HI

[2]

[Anonymous], 2013, 2013 GLOBAL FACT SHE, P1

[3]

[Anonymous], 2009, DIVISION AIDS TABLE, V39, P1

[4] Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200?mg twice daily to nevirapine extended release 400?mg once daily (TRANxITION) [J].

Arasteh, K. ;

Ward, D. ;

Plettenberg, A. ;

Livrozet, J. M. ;

Orkin, C. ;

Cordes, C. ;

Guo, J. ;

Wang, E. ;

Yong, C. L. ;

Robinson, P. ;

Quinson, A. .

HIV MEDICINE, 2012, 13 (04) :236-244

[5] Immediate antiretroviral therapy in young HIV-infected children: benefits and risks [J].

Collins, Intira J. ;

Judd, Ali ;

Gibb, Diana M. .

CURRENT OPINION IN HIV AND AIDS, 2014, 9 (01) :87-94

[6] Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients [J].

Gathe, Joseph ;

Andrade-Villanueva, Jaime ;

Santiago, Steven ;

Horban, Andrzej ;

Nelson, Mark ;

Cahn, Pedro ;

Bogner, Johannes ;

Spencer, David ;

Podzamczer, Daniel ;

Yong, Chan-Loi ;

Thuy Nguyen ;

Zhang, Wei ;

Drulak, Murray ;

Quinson, Anne-Marie .

ANTIVIRAL THERAPY, 2011, 16 (05) :759-769

[7] Steady-state Pharmacokinetics of Nevirapine Extended-release Tablets in HIV-1-infected Children and Adolescents An Open-label, Multiple-dose, Cross-over Study [J].

Giaquinto, Carlo ;

Anabwani, Gabriel ;

Feiterna-Sperling, Cornelia ;

Nuttall, James ;

Mompati, Kgosidialwa ;

Koenigs, Christoph ;

Mensa, Federico J. ;

Sabo, John P. ;

Yong, Chan-Loi ;

MacGregor, Thomas R. ;

Thuy Nguyen ;

Quinson, Anne-Marie .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (07) :E173-E179

[8] Safety of Perinatal Exposure to Antiretroviral Medications: Developmental Outcomes in Infants [J].

Sirois, Patricia A. ;

Huo, Yanling ;

Williams, Paige L. ;

Malee, Kathleen ;

Garvie, Patricia A. ;

Kammerer, Betsy ;

Rich, Kenneth ;

Van Dyke, Russell B. ;

Nozyce, Molly L. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (06) :648-655

[9]

U.S. Department of Health and Human Services, Guidelines for the use of antiretroviral agents in adults and adolescents with HIV

← 1 →